Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Zynerba Shares Cut In Half After Phase 2 Trial Doesn’t Meet Primary Endpoint

Courtesy of Benzinga.

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares are trading lower by $8.50, or 56 percent, at $6.50 in Monday’s session.

Before the open, the company announced top-line results from Phase 2 Star 1 trial of ZYN002 for treatment of adult epileptic patients with focal seizures didn’t meet its primary endpoint.

See Also: What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals

After a lower open, Zynerba had a brief bounce to $6.75 before continuing its move lower. So far, the ensuing decline has taken the stock to $5.93, but rebounded back into the mid-$6.00 handle. That low comes in just above March 2015 low ($5.75).

Its all-time low was made the month prior at $4.64.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!